Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure

Clinical Cancer Research

Volumn 3, Issue 10, 1997, Pages 1731-1738

  Danks, Mary K ^a   Pawlik, Cynthia A ^a   Whipple, David O ^a   Wolverton, Judith S ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPLEX FORMATION; COVALENT BOND; CYTOTOXICITY; DRUG EFFECT; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; MEDULLOBLASTOMA; PRIORITY JOURNAL; TISSUE CULTURE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CELL DIVISION; CHILD; CULTURE MEDIA; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; DRUG ADMINISTRATION SCHEDULE; DRUG STABILITY; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MEDULLOBLASTOMA; MICE; MICROSCOPY, FLUORESCENCE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; TOPOISOMERASE I INHIBITORS; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 0030765192     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Allan, Y. C., and Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 34: 191-218, 1994.
2. Tanizawa, A., Kohn, K. W., Kohlhagen, G., Leteurtre, R., and Pommier, Y. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry, 34: 7200-7206, 1995.
3. Beidler, D. R., and Cheng, Y-C. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol. Pharmacol., 47: 907-914, 1995.
4. O'Connor, P. M., Nieves-Neira, W., Kerrigan D., Bertrand, R., Goldman, J., Kohn, K. W., and Pommier, Y. S-Phase population analysis does not correlate with the cytotoxicity of camptothecin and 10-11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Commun., 3: 233-240, 1991.
5. Danks, M. K., Garrett, K. E., Marion, R. C., and Whipple, D. O. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res., 56: 1664-1667, 1996.
6. Tubergen, D. G., Stewart, C. F., Pratt, C. B., Zamboni, W. C., Winick, N., Santana, V. M., Dryer, Z. A., Kurtzberg, J., Beil, B., Grier, H., and Vietti, T. J. Phase I trial and pharmacokinetic and pharmacodynamics study of topotecan using a five-day course in children with refractory solid tumors: a Pediatric Oncology Group study. J. Pediatr. Hematol-Oncol., 18: 352-361, 1996.
7. van Warmerdam, L. J. C., Verweij, J., Schellens, J. H. M., Rosing, H., Davies, B. E., de Boer-Dennert, M., Maes, R. A. A., and Beijnen, J. H. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother. Pharmacol., 35: 237-245, 1995.
8. Grochow, L. B., Rowinsky, E. K., Johnson, R., Ludeman, S., Kaufmann, S. H., McCabe, F. L., Smith, B. R., Hurowitz, L., deLisa, A., Donehower, R. C., and Noe, D. A. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab. Dispos., 20: 706-713, 1992.
9. Rowinsky, E. K., Adjei, A., Donehower, R. C., Gore, S. D., Jones, R. J., Burke, P. J., Cheng, Y-C., Grochow, L. B., and Kaufmann, S. H. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J. Clin. Oncol., 12: 2193-2203, 1994.
10. Saylors, R. L., III, Sidransky, D., Friedman, H. S., Bigner, S. H., Bigner, D. D., Vogelstein, B., and Brodeur, G. M. Infrequent p53 gene mutations in medulloblastomas. Cancer Res., 51: 4721-4723, 1991.
11. Baker, S. D., Wadkins, R. M., Stewart, C. F., Beck, W. T., and Danks, M. K. Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy. Cytometry, 19: 134-145, 1995.
12. Locket, S. J., O'Rand, M., Rinehart, C. A., Kaufman, D. G., Herman, B., and Jacobson, K. Automated fluorescence image cytometry: DNA quantification and detection of Chlamydial infections. Anal. Quant. Cytol. Histol., 13: 27-44, 1991.
13. Pizao, P. E., Smitskamp-Wilms, E., Van Ark-Otte, J., Beijnen, J. H., Peters, G. J., Pinedo, H. M., and Giaccone, G. Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin on sub- and post-confluent tumor cell cultures. Biochem. Pharmacol., 48: 1145-1154, 1994.
14. Yang, C. J., Horton, J. K., Cowan, K. H., and Schneider E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res., 55: 4004-4009, 1995.
15. Perego, P., Capranico, G., Supino, R., and Zunino, R. Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anti-Cancer Drugs, 5: 645-649, 1994.
16. Woessner, R. D., Eng, W. K., Hofmann, G. A., Rieman, D. J., McCabe, F. L., Hertzberg, R. P., Mattern, M. R., Tan, K. B., and Johnson, R. K. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol. Res., 4: 481-484, 1992.
17. Dubrez, L., Goldwasser, F., Genne, P., Pommier, Y., and Solary, E. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia (Baltimore), 9: 1013-1024, 1995.
18. Mikhaylova, V. T., and Markov, D. V. Spherical bodies and fibrillar centers in hepatic cell nucleoli of rats treated with D-galactosamine. Exp. Cell Res., 212: 10-21, 1994.
19. DelBino, G., Lassota, P., and Darzynkiewicz, Z. The S-phase cytotoxicity of camptothecin. Exp. Cell Res., 193: 27-35, 1991.
20. Saltz, L., Sirott, M., Young, C., Tong, W., Niedzwiecki, D., Tzy-Jyun, Y., Tao, Y., Trochanowski, B., Wright, P., Barbosa, K., Toomasi, F., and Kelson, D. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J. Natl. Cancer Inst., 85: 1499-1507, 1993.
21. Holm, C., Covey, J. M., Kerrigan, D., and Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res., 49: 6365-6368, 1989.
22. Murren, J. R., Fedele, J., Anderson, S., Pizzorno, G., Beidler, D., Flynn, S., and Cheng, Y-C. Topotecan induces rapid decrease in intracellular topoisomerase I concentration in peripheral mononuclear cells. Proc. Am. Assoc. Cancer Res., 36: 242, 1995.
23. Buckwalter, C. A., Lin, A. H., Tanizawa, A., Pommier, Y. G., Cheng, Y-C., and Kaufmann, S. H. RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. Cancer Res., 56: 1674-1681, 1996.
24. Hadjiolova, K., Rose, K. M., and Scheer, U. Immunolocalization of nucleolar proteins after D-galactosamine-induced inhibition of transcription in rat hepatocytes. Exp. Cell Res., 165: 481-493, 1986.
25. Yang, S. W., Burgin, A. B., Jr., Huizenga, B. N., Robertson, C. A., Yao, K. C., and Nash, H. A. A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerdses. Proc. Natl. Acad. Sci. USA, 93: 11534-11539, 1996.